Whenever in trouble Buy!

Discussion in 'Pfizer' started by Anonymous, Apr 28, 2014 at 10:47 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Ian to repeat history from Jeffrey Kindler, buy,buy, buy watch value drop and walk away with hundreds of millions of dollars leaving someone else with the bag. Kindler who gave himself a 10Million dollar raise after his buying spree (from 14 Million to 24 Million). What kind of raise do you expect Ian to get with a 100Billion dollar acquisition. Instead of being held accountable for our current portfolio he will distract investors by buying AZ and selling off 2/3 of current Pfizer in the coming years, so he is known for the restructuring CEO. AZ like Pfizer is heading over the cliff and we need a pipeline but not the personal. Only last year we were told that Pfizer does not want to be the biggest anymore, but as the Eliquis and Xelganz numbers started coming in at first quarter meeting and it was clear Celebrex is going away early. The shit hit the fan! Some finance genius realized that we could save tons of money by keeping the money in Europe and not paying U.S. taxes so lets try to buy our way out of trouble one more time. The hostile takeover of AZ will buy Pfizer a few more years but AZ is no prize. AZ like Pfizer can't sell Brillinta even with great data in the current U.S. Obama Care climate. As we wring out cost savings by buying AZ, the problem will not go away. Plan on hearing about record compensation for Pfizer/AZ Executives in the coming year.
     

  2. Anonymous

    Anonymous Guest

    AZ is a very good fit for Pfizer. Do your research.
     
  3. Anonymous

    Anonymous Guest

    The 1st poster is spot on. Ion is brilliant when you can no longer get the results W/Street is looking for do the big acquisition and distract every one for two or three years and ride into the sun set.
     
  4. Anonymous

    Anonymous Guest

    AZ is a great fit for Pfizer. Oncology future sprinkled with cardiovascular and Diabetes. But given this is a cost saving move and becoming so large has to hedge our bet that just one drug will hit it big. This will be a blood bath at AZ! Forbes today: Pfizer says the deal is being driven by the complementary nature of the two drug giants’ stables of products and by the costs it could cut, but it would also move its tax domicile to a holding company in the U.K. and therefore pay a significantly lower tax rate. This is known as a “tax inversion.”
     
  5. Anonymous

    Anonymous Guest

    President Obama has already made a big move against tax inversions. His proposed 2015 budget, which is unlikely to pass in its current form, contains a provision designed to prevent inversions from happening. Current law allows companies to reincorporate elsewhere if they execute a deal that transfers 20% of their shares to owners overseas. The Obama proposal would require a company to have 50% ownership outside the U.S.. Pfizer will try to get out of dodge fast!!! So much for Ian gaining respect of the company back.
     
  6. Anonymous

    Anonymous Guest

    As if Obama's budget would pass. Never has. Never will. Oh yes the boy genius even has it called the "obama budget". Lol. He's a juvenile signing things that other people like soros tell him to sign. Empty suit. Obama budget doa as always. Lol, did he ever even study economics 101? Accounting 101? He's a freeloader, as his wife us also. The joke is on all of us now but puh-leaze, do yourself a favor: don't put stock in an obama budget proposal.
     
  7. Anonymous

    Anonymous Guest

  8. Anonymous

    Anonymous Guest

    Please give it a rest!! You're becoming tedious with your hate. Stick to topic.

    Find another blog or site to talk politics. Most of us agree with the message, we're tired of negative rambling.
     
  9. Anonymous

    Anonymous Guest

    At a high level presentation last year Pfizer insisted they don't want to be the biggest anymore. We are more concerned with gaining public image back then actually selling our medicine. I suspect that Pfizer will be the talk of mid term elections as an example of the largest U.S. tax dodging company and when they finally settle on a price for AZ 100+Billion the public will demand a price reductions on our medicine.

    While the AZ deal would be synergistic, don't be surprised if the industry implodes with negative press tarnishing our image that is currently viewed as less trusting then tobacco industry.
     
  10. Anonymous

    Anonymous Guest

    Op is spot on. With the new BU structure and platform structure, Pfizer has lost its ability to execute. In the overseas country offices, the Country Manager no longer calls the shots. The BUs are undercutting each other and platform lines have been so badly cut that basically they are reduced to saying that's not my job. Unlike Pfizer, BMS with Yervoy, Gilead with Sovaldi, Merck with Januvia, Gardasil, Novartis with their Oncology portfolio, GSK with Pazopanib have shown that it is still possible to execute in this difficult payer environment.
     
  11. Anonymous

    Anonymous Guest

    If obama would stop his stupid selfies and actually do something with any relevance is another story all together. A fool of a pres voted for by uninformed who needed to see any person of color elected
     
  12. Anonymous

    Anonymous Guest

    Of course there will be some complementary disease states and expansion in the mix of these two companies, but how could anyone be fooled by this strategy at this point. This potential takeover is about nothing more that finding a few more years of stability with the Celebrex, Zyvox, and other patent cliff issues, and incorporating in the UK and paying lower corporate rate taxes. Its known as "tax deversion". You people need to read more than one article on the subject.
     
  13. Anonymous

    Anonymous Guest

    Ibba ibs "tax diversion" ideyot!
     
  14. Anonymous

    Anonymous Guest

    Actually this is extortion. Give me the sweet tax deals or we leave the USA. This is very sad for a great american company but what do you expect from a guy from Scotland running the company.
     
  15. Anonymous

    Anonymous Guest

    This individual wasn't the first to initiate Obama's name into the discussion. Why don't you go after the poster who first mentioned Obama--oh, right, because you agree with their position and are just another adoring empty head when it comes to Obama. You're a no brain liberal hack who calls foul any time someone purports a cogent argument involving Obama that doesn't jive with your spread the wealth mindset.
     
  16. Anonymous

    Anonymous Guest

    Wait until you see how far we move to the left during two terms of 'Billary' Clinton! Your name calling had better be kept anonymous, because they're going to be able to get you for hate speech. Back to the topic, please: unless you make less than $85,000 or are REALLY connected to Carl W or one of his minion RBDs, you probably won't be working here for another 3 years, anyway.
     
  17. Anonymous

    Anonymous Guest

    As a Searle employee who was purchased by Pharmacia then Pfizer, and then as a Wyeth employee for 8 years purchased by Pfizer again, I would suggest looking at AZ and the tax inversion as a sound strategy. Post inversion in the UK if successful, Pfizer, a fine merger and acquisition company will be looking for the next innovative, complementary deal. As an employee who has subsequently left on their own despite being retained through every acquisition, I would suggest trying to be open minded about the excellent corporate training Pfizer offers and embrace the change. I am far better equipped having done two stints at Pfizer to navigate the marketplace and may ending up being there again someday. Good luck to all!